Embed Size (px)
DESCRIPTION
Hilleman Laboratories is a joint-venture between Merck & Co., a global research-driven pharmaceutical company and Wellcome Trust, a global charitable foundation dedicated to achieving extraordinary improvements in Child Health.
Citation preview
Our commitment to Global Health
WELCOME TO HILLEMAN LABORATORIES
Bridging scientific research and industry to develop effective, affordable and sustainable
vaccines for developing world.
Developing Vaccines for Global Health
Tomorrow... is our concern and we care
Developing immunity.. Promising well being
Life is precious.. Vaccination to preserve it
Protecting life and ensuring healthy growth
Affordable and accessible vaccines forthe developing nations
OUR IDENTITYHillemanlabs @ Nanotechnology Building, Jamia Hamdard
Striving towards a healthier world since September 2009
Joint Initiative to build a vaccine R&D facility with focus on developing world
Devoted team of 30 scientists with expertise in Vaccine Development and Testing
Operating with core divisions of Upstream, Downstream, Formulations and Analytical Labs
Mission to develop thermo stable, efficacious and affordable vaccines
DR. MAURICE HILLEMANA Pioneer in Vaccine Development
"Discoveries of the cause for diseases and their prevention by vaccines... have been a hallmark for twentieth century medicine and provide a remarkable heritage for the people of the future."
Maurice R.Hilleman, PhD, DScSenior Vice President, 1957-1984
Merck Sharp & Dohme Research Laboratories
OUR APPROACH
HL carries out R&D and Clinical Assessment activities to develop vaccines for diseases that constitute almost 90% of the global burden of
diseases
HL carries out R&D and Clinical Assessment activities to develop vaccines for diseases that constitute almost 90% of the global burden of
diseases
HL is forging partnerships with Government, Policy Makers, Public & Private Enterprises, Research Institutes and NGOs to strengthen public health
systems and immunization programs
HL is forging partnerships with Government, Policy Makers, Public & Private Enterprises, Research Institutes and NGOs to strengthen public health
systems and immunization programs
OUR APPROACH
Apply
Focus
Partner
OUR VISION
Philanthropy
Science
Business
OUR DREAM
Vaccine for every child
Immunize and protectHealthier force of tomorrow
Facility (GLP class)
Scientists
Infrastructure
Novel ImmunizationPlatform (HL)
OUR COMMITMENT
Reduced footprint and affordability
Thermostability
Ease of administration
OUR ADVISORS
(Director, Emory Vaccine Center)
Dr. Rafi Ahmed
Executive Director, Icddr,b Dhaka, Bangladesh
Dr. John Clemens
(Prof. & Chairman Dept. of Pediatrics & Child Health, Aga Khan UMC, Pakistan)
Dr. Zulfiqar Bhutta
(Assistant Director-General, Health Systems and Innovation)
Dr. Marie-Paule Kieny
(Board Member and Advisor for Foundations in Switzerland, Uganda, Thailand and US)
Timothy Nielander
(CEO, The Global Partnership for Education)
Alice Albright (President & Chief Executive Officer, Vedantra)
Dr. Allan Shaw
(Chairman, African Leaders Malaria Alliance and Chairman, Board AIDS Fund)
Ms. Joy Phumaphi
(President, Health Foundation of India)
Dr. K. SrinathReddy
Ms. Helen ReesProfessor of Medicine, Global Health, and PediatricsAssociate Director, Emory Vaccine CenterDirector, Emory Vaccine Policy and Development
Walter A. Orenstein, MD
Professor Helen Rees OBE MB BChir, MA (CANTAB), MRCGP, DCH, DRCOG
Mr. Michel Greco
Former President of Aventis Pasteur
OUR BOARD MEMBERS
Director, Hilleman Laboratories(Senior Vice President and Head, Global Vaccine Franchise, Merck)
Dr. James R. Baker
Director, Hilleman Laboratories(President – Vaccine Division, Merck)
Dr. Julie Gerberding
Director, Hilleman Laboratories(Director – Technology Transfer, Wellcome Trust)
Dr. A.E. Bianco
Director, Hilleman Laboratories(Senior Vice President, Manufacturing Division, Merck)
Sanat Chattopadhyay
Director, Hilleman Laboratories(Chief Operating Officer, Wellcome Trust)
Simon Jeffreys
(Chairman, Hilleman Laboratories)
Dr. Gerd Zeittlmeissl
Director – Hilleman Laboratories(Head of Microbial Pathogenesis (Sanger Center))
Prof. Gordon Dougan
OUR MANAGEMENT
Chief Executive Officer (MSD Wellcome Trust, Hillemanlabs)
Dr. Davinder Gill
Vice President - Finance & Company Secretary, (MSD Wellcome Trust, Hillemanlabs)
Mr. Naveen K Amar
Vice President - HR, Admin & IT, (MSD Wellcome Trust Hillemanlabs)
Mr. JaideepMukherjee Vice President -
Business Development (MSD Wellcome Trust, Hillemanlabs)
Mr. Atin Tomar
Vice President – R&D
Dr. Zimra Israel
VACCINE RESEARCH OVERVIEW
01 02 03 04
05 06 07 08
Antigen Identification
Candidate screening
Responsiveness
Host Protection
Immunogenicity
Toxicity
Selection
Immune response
Responsiveness in large cohort
Antigen Production (Laboratory-scale)
Screening of growth medium
Screening of growth parameters
Manufacturing(Industrialscale)
Process Scale-up
Process optimization
Clinical Trail (Phase I)Safety
Non-endemic Healthy Adults> 20
About 3 months
Adverse effects
Clinical Trial (Phase II)Immunogenicity
Endemic infected/noninf.>100
About 3 years
Immune responses
Clinical Trail (Phase III)Efficacy
Endemic infected/healthy>1000
Up to 5 years Protection
VACCINE RESEARCH OVERVIEW
Hilleman Laboratories works extensively to bridge the gap between current vaccine candidate reliance on cold chain and low accessibility & build a new platform technology for development of thermo-stable and affordable vaccines
The current project undertaken at Hilleman Laboratories is to heat stabilize the existing vaccine candidate
Development of a thermo-stable oral thin film or granule-based rotavirus vaccine to allow for greater stability and reduce cold chain burden
Hilleman laboratories is open to collaboration for development of innovative vaccine delivery methods to develop the initial assay for the project
Hilleman Labs first project to focus on affordable access to life-saving Rotavirus vaccine to resource limited nations
R&D AT HILLEMAN LABORATORIES
Microbial and Mammalian culture Filtration and chromatographic separation
Formulation development and lyophilization/spray-dryiing
R&D AT HILLEMAN LABORATORIES
Screening and Identifying potential candidates with focus on heat stabilization
Seeding virus – cell culture – potency assay – Formulation Development
Pre-clinical evaluation – viability for commercial scale-up – Development of Delivery technology
Up-Stream Process Downstream Process Formulation & Analytics
Marketing and Distribution
Phase 3
Large Scale Manufacturing
Late Development Phase IIIClinical Trial
-> Registration
R&D AT HILLEMAN LABORATORIES
Phase 2
Early DevelopmentLead –> Phase I /II Clinical Trial
Phase 1
Basic Research Target -> Lead Candidate
R&D AT HILLEMAN LABORATORIES
Global Vaccine Needs
Feasibility
HillemanStrengths
Trans-HL management and advisory group consultation for program synergy
HL Lead Project
HL ScientificAdvisory
LeadershipProjects adopted
HL LeadershipProgram Plan
ReviewReview Strengths, Weakness
Research Proposal(from extramural, intramural, biotech, foundation)
R&D AT HILLEMAN LABORATORIES
Up-Stream Process Downstream Process Analytical
OUR CULTURE
Latest happenings
Best IndustrialPartnership in India
HOW WE PERCEIVE THE FUTURE
HILLEMAN LABORATORIES PVT. LTD.
Hilleman Laboratories Pvt. Ltd.2nd Floor, Nanotechnology Building, Jamia Hamdard, Hamdard Nagar,New Delhi – 110062 India.
Ph: +91 (11) 3099 7700Fax: +91 - (11) 3099 7711
Email: [email protected]: www.hillemanlabs.org
Office Contact:
